Document 0804
 DOCN  M9590804
 TI    Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as
       primary prophylaxis against Pneumocystis carinii pneumonia in patients
       with human immunodeficiency virus. Dutch AIDS Treatment Group.
 DT    9509
 AU    Schneider MM; Nielsen TL; Nelsing S; Hoepelman AI; Eeftinck Schattenkerk
       JK; van der Graaf Y; Kolsters AF; Borleffs JC; Department of Internal
       Medicine (Section of Immunology and; Infectious Diseases), University
       Hospital Utrecht, Netherlands.
 SO    J Infect Dis. 1995 Jun;171(6):1632-6. Unique Identifier : AIDSLINE
       MED/95287064
 AB    The efficacy and toxicity of trimethoprim-sulfamethoxazole (TMP-SMZ) as
       primary prophylaxis against Pneumocystis carinii pneumonia (PCP) for
       patients with human immunodeficiency virus (HIV) infection was assessed
       by comparing the effects of two dosages (480 or 960 mg once a day) of
       the drug. The multicenter trial involved 260 HIV-infected patients with
       CD4 cell counts < 0.2 x 10(9)/L and no history of PCP. Patients were
       randomly assigned to the treatment groups. After a median follow-up of
       376 days (range, 1-1219), none of the patients developed PCP. Most
       adverse reactions that required discontinuation were seen within the
       first month of TMP-SMZ use and were seen more frequently and earlier in
       the 960-mg group (hazard ratio, 1.4; 95% confidence interval, 0.95-2.02;
       P = .007). For patients with HIV infection, 480 mg of TMP-SMZ is as
       efficacious as but less toxic than 960 mg of the drug for primary
       prophylaxis against PCP.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY  Adult  Aged
       Dose-Response Relationship, Drug  Human  Middle Age  Pneumonia,
       Pneumocystis carinii/*PREVENTION & CONTROL
       Sulfamethoxazole/*ADMINISTRATION & DOSAGE  Support, Non-U.S. Gov't
       Survival Analysis  Toxoplasmosis/COMPLICATIONS
       Trimethoprim/*ADMINISTRATION & DOSAGE  CLINICAL TRIAL  JOURNAL ARTICLE
       MULTICENTER STUDY  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).